David E.I. Pyott's most recent trade in Tarsus Pharmaceuticals Inc was a trade of 3,837 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2026 | 3,837 | 3,837 | - | - | Stock Option (right to buy) | |
| Tarsus Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2026 | 2,417 | 2,417 | - | - | Restricted Stock Units | |
| Tarsus Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2026 | 806 | 806 | - | - | Restricted Stock Units | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 3,830 | 5,412 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 3,830 | 0 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 299.87 per share. | 01 Jun 2026 | 1,222 | 2,094 (0%) | 0% | 299.9 | 366,441 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 298.91 per share. | 01 Jun 2026 | 1,175 | 3,316 (0%) | 0% | 298.9 | 351,219 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 297.71 per share. | 01 Jun 2026 | 921 | 4,491 (0%) | 0% | 297.7 | 274,191 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 300.72 per share. | 01 Jun 2026 | 495 | 1,599 (0%) | 0% | 300.7 | 148,856 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 302.65 per share. | 01 Jun 2026 | 17 | 1,582 (0%) | 0% | 302.6 | 5,145 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2026 | 1,441 | 1,441 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2026 | 671 | 1,582 (0%) | 0% | 0 | Common Stock | |
| Tarsus Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2026 | 1,383 | 1,383 | - | - | Common Stock | |
| Tarsus Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2026 | 1,383 | 0 | - | - | Restricted Stock Units | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 30,000 | 30,000 | - | - | Common Stock (Right to Buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 775 | 911 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 24 Mar 2025 | 7,440 | 7,576 (0%) | 0% | 89.0 | 661,788 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 7,440 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 299.00 per share. | 24 Mar 2025 | 7,440 | 136 (0%) | 0% | 299 | 2,224,560 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 17,560 | 7,440 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 220.00 per share. | 24 Jun 2024 | 17,560 | 15,026 (0%) | 0% | 220 | 3,863,200 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 24 Jun 2024 | 17,560 | 17,696 (0%) | 0% | 89.0 | 1,561,962 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 7,470 | 3,780 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 222.00 per share. | 24 Jun 2024 | 7,470 | 136 (0%) | 0% | 222 | 1,658,340 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.99 per share. | 24 Jun 2024 | 7,470 | 32,586 (0%) | 0% | 72.0 | 537,765 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.20 per share. | 24 Jun 2024 | 7,420 | 25,116 (0%) | 0% | 70.2 | 520,884 | Common Stock |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 7,420 | 3,830 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 221.00 per share. | 24 Jun 2024 | 7,420 | 7,606 (0%) | 0% | 221 | 1,639,820 | Common Stock |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Biomarin pharma Inc - Registered Shares | David E.I. Pyott | Director | 21 May 2024 | 4,720 | 49,750 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Biomarin pharma Inc - Registered Shares | David E.I. Pyott | Director | 23 May 2023 | 4,190 | 45,030 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 136 | 136 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 136 | 0 | - | - | Restricted Stock Units | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Biomarin pharma Inc - Registered Shares | David E.I. Pyott | Director | 24 May 2022 | 4,980 | 40,840 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 136 | 136 | - | - | Restricted Stock Units |